EverHint – Dip & Bounce Mean Reversion for Mar 16, 2026 – 9 Signals – Healthcare Leads (3)

What This Signal Is (Quick)

This strategy identifies stocks that experienced a controlled intraday flush followed by a same-day bounce, creating a classic "dip & bounce" pattern:

• Signal Type (DIP_BOUNCE_LONG): Buy-side signals only (v1)
  • Stock dipped meaningfully below previous day's close during today's session
  • Stock bounced off the intraday low and closed well above it
  • Day often finishes red or flat, but with a clear lower tail/wick showing buyers stepped in

Pattern Requirements:

• Dip vs Previous Close: Today's low trades significantly below yesterday's close (≥1.5% dip)
• Bounce Off Low: Price recovers intraday and closes meaningfully above the session low (≥0.75% bounce)
• Net Result: Stock still often down or flat for the day (-2.5% to +0.5%), but with visible buying pressure

Key Characteristics:

• Mean reversion focus (not trend following)
• Targets 1-3 day bounce plays or short-term swing trades
• Looks for "flush then absorb" patterns with controlled selloffs
• Complements trend-following strategies (EMA crossovers) by catching short-term dips

Best For:

• Traders who like buying controlled dips with visible buying pressure
• Scanning for intraday flush patterns across the whole market
• Manually picking 1-2 best setups for short-term trades

Key Criteria:

• Minimum dip: 3.3% (open to intraday low)

• Minimum bounce: 1.0% from low

• Net change range: -2.0% to +0.3%

• Price above SMA(200)

• Minimum ADV: $40M

Holding Period: 1-5 days
Risk Level: Medium

How We Ranked Today

Ranked by dip magnitude (highest first)

📊 Dip & Bounce Mean Reversion Signals (9 Total)

Ranked by dip_percent:

Field Notes

Sector concentration: Healthcare (3), Basic Materials (2), Utilities (1)

Insider selling: RKLB (Rocket Lab USA, Inc., $-24.5M), WDC (Western Digital Corporation, $-6.7M), SYRE (Spyre Therapeutics, Inc., $-860K)

Near-term earnings: CTMX (CytomX Therapeutics, Inc.) report within 7 days. Higher volatility risk.

Data coverage: 55.6% insider, 0.0% congressional, 100.0% earnings, 100.0% analyst, 66.7% news

Peer Analysis

Understanding how these stocks relate to their industry peers:

NSA (National Storage Affiliates Tru): Leads 8 peers: LXP ($47.81, +2.4%), DEI ($9.61, -1.3%), IVT ($31.67, +1.4%), EPR ($56.25, +0.4%), PSA ($289.80, -2.7%) | Peer of: CURB ($26.71, +0.7%), DBRG ($15.40, +0.2%), DEI ($9.61, -1.3%) and 4 more

APD (Air Products and Chemicals, Inc): Leads 9 peers: VALE ($15.05, +2.5%), ECL ($273.11, -0.4%), FCX ($57.91, +2.8%), CTVA ($79.04, -0.2%), WPM ($139.19, -0.5%) | Peer of: CC ($17.64, +0.4%), CTVA ($79.04, -0.2%), ECL ($273.11, -0.4%) and 4 more

CE (Celanese Corporation): Leads 10 peers: BCPC ($168.36, -0.4%), SXT ($88.41, -0.8%), CBT ($68.64, -1.2%), SSL ($11.85, +4.8%), TMC ($6.09, +2.0%) | Peer of: CBT ($68.64, -1.2%), SSL ($11.85, +4.8%), SXT ($88.41, -0.8%) and 1 more

WDC (Western Digital Corporation): Leads 10 peers: STX ($398.78, +3.9%), NXPI ($191.89, +0.5%), MPWR ($1077.40, +2.4%), SMCI ($31.86, +3.6%), EA ($200.21, +0.5%) | Peer of: DDOG ($126.57, +1.6%), DELL ($156.59, +3.3%), EA ($200.21, +0.5%) and 7 more

CTMX (CytomX Therapeutics, Inc.): Leads 9 peers: ERAS ($13.51, -0.8%), IOVA ($4.04, +2.0%), MBX ($29.80, +6.4%), AVBP ($24.31, +1.7%), MGTX ($7.69, +4.1%) | Peer of: AVXL ($4.71, +1.3%), ERAS ($13.51, -0.8%), GYRE ($7.50, -0.7%) and 4 more

CWEN (Clearway Energy, Inc.): Leads 10 peers: ORA ($109.69, -0.6%), BEPC ($40.50, +3.3%), BEP ($30.65, +1.6%), CIG-C ($3.06, +4.8%), CIG ($2.28, +3.6%) | Peer of: BEP ($30.65, +1.6%), BEPC ($40.50, +3.3%), BIPC ($46.24, -1.2%) and 3 more

PLSE (Pulse Biosciences, Inc): Leads 8 peers: STAA ($18.08, -4.0%), LFMD ($4.40, +10.6%), IMTX ($9.81, +6.2%), OPK ($1.19), DNTH ($78.00, +0.2%) | Peer of: BLFS ($19.08, +3.9%), COLL ($35.62, +3.2%), GDRX ($2.22, -0.9%) and 3 more

SYRE (Spyre Therapeutics, Inc.): Leads 9 peers: PHVS ($26.93, +5.9%), IMNM ($20.36), WVE ($12.41, -4.7%), NTLA ($13.38, +4.9%), ZYME ($23.62, +3.2%) | Peer of: ABCL ($3.56, +2.0%), ARDX ($5.84, +1.0%), AZTA ($20.91, -2.4%) and 11 more

RKLB (Rocket Lab USA, Inc.): Leads 9 peers: HEI ($291.47, +1.1%), UAL ($90.28, +4.2%), WAB ($239.20, +1.0%), VRSK ($204.74, +1.8%), OTIS ($83.61, +0.5%) | Peer of: BE ($153.68, -0.5%), EME ($726.55, +2.3%), UAL ($90.28, +4.2%) and 2 more

Recent Headlines

APD (Air Products and Chemicals, Inc)

• 44 Wealth Management LLC Sells 6,182 Shares of Air Products and Chemicals, Inc. $APD (source)
• Air Products and Chemicals, Inc. (NYSE:APD) Receives Consensus Rating of “Moderate Buy” from Analysts (source)
• APD to Showcase Freshline IQ Freezer at Seafood Expo North America (source)
• APD to Showcase Freshline IQ Freezer at Seafood Expo North America (source)
• Air Products to Highlight its Freshline® IQ Freezer and Food Freezing Solutions at Seafood Expo North America (source)
• Air Products to Highlight its Freshline® IQ Freezer and Food Freezing Solutions at Seafood Expo North America (source)
• Air Products' Executive Leadership to Speak at J.P. Morgan Industrials Conference on March 18 (source)
• Air Products' Executive Leadership to Speak at J.P. Morgan Industrials Conference on March 18 (source)
• Goldman Sachs Large Cap Equity Fund Q4 2025 Portfolio Activity (source)
• Air Products and Chemicals, Inc. $APD Shares Acquired by Barrow Hanley Mewhinney & Strauss LLC (source)

CE (Celanese Corporation)

• Celanese Price Prediction: Iran Conflict Pushes CE Price Target to $81 (source)
• Dynamic Technology Lab Private Ltd Invests $450,000 in Celanese Corporation $CE (source)
• Celanese Corporation (NYSE:CE) Receives Average Rating of “Hold” from Analysts (source)

CTMX (CytomX Therapeutics, Inc.)

• Mid-Cap CytomX Therapeutics' Colorectal Cancer Data Fuels Stock Rally (source)
• CytomX Therapeutics, Inc. (CTMX) Q4 2025 Earnings Call Transcript (source)
• CytomX Therapeutics (CTMX) Reports Q4 Loss, Misses Revenue Estimates (source)
• CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update (source)
• CytomX's Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer (source)
• CytomX Therapeutics Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts (source)
• CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Rating of “Moderate Buy” from Brokerages (source)

NSA (National Storage Affiliates Tru)

• NSA Stock Alert: Halper Sadeh LLC is Investigating Whether National Storage Affiliates Trust is Obtaining a Fair Price for its Shareholders (source)
• Public Storage to Acquire National Storage Affiliates in $5.7 Billion Stock Deal (source)
• Public Storage to Acquire National Storage Affiliates, Creating Significant Value for All Stakeholders (source)
• Land & Buildings Loads Up National Affiliates Storage Trust With 1.3 Million Shares (source)

SYRE (Spyre Therapeutics, Inc.)

• Spyre Therapeutics, Inc. $SYRE Shares Bought by B Group Inc. (source)

WDC (Western Digital Corporation)

• Cinctive Capital Management LP Sells 108,435 Shares of Western Digital Corporation $WDC (source)
• Banco Bilbao Vizcaya Argentaria S.A. Buys 11,330 Shares of Western Digital Corporation $WDC (source)
• Alliancebernstein L.P. Purchases 210,600 Shares of Western Digital Corporation $WDC (source)
• Apis Capital Advisors LLC Purchases New Shares in Western Digital Corporation $WDC (source)
• Alight Capital Management LP Invests $4.80 Million in Western Digital Corporation $WDC (source)
• FORA Capital LLC Takes $2.76 Million Position in Western Digital Corporation $WDC (source)
• Bank of Hawaii Takes $5.42 Million Position in Western Digital Corporation $WDC (source)
• Western Digital (WDC) Falls More Steeply Than Broader Market: What Investors Need to Know (source)
• Western Digital (WDC) Is Considered a Good Investment by Brokers: Is That True? (source)
• Western Digital Surges 540% in a Year: Is the Stock Worth Buying? (source)
• Cramer: Buy Western Digital, Micron, Seagate on oil-driven dips (source)

Market Context

Broad market indices are showing modest gains, with the Dow leading at +0.47%, followed by the S&P 500 at +0.38% and Nasdaq at +0.17%. This upward trend across major benchmarks reflects steady risk appetite, supporting dip bounce strategies like v2 reclaim, where pullbacks are expected to recover prior levels. In this environment, intraday dips may offer reliable entry points for bounces, as the overall positive momentum encourages buying on weakness rather than sustained selling.

The VIX at 23.69, down sharply by 8.46%, indicates elevated but rapidly easing volatility. While still above typical calm levels, the decline suggests diminishing fear and potentially shallower intraday swings, which favors dip bounce plays by reducing the risk of oversold conditions turning into deeper corrections. Traders can capitalize on these controlled fluctuations, as the calming volatility aligns with the strategy's reliance on quick reclamations without extreme whipsaws.

Healthcare emerging as the top sector amid nine total signals points to subtle rotation toward defensive areas, even as broader indices advance. This dynamic enhances the v2 reclaim setup, blending cyclical strength with sector stability, where dips in healthcare names are likely to attract buyers in a risk-on climate tempered by falling volatility.

Vlad's Take (EverHint)

Today's signals: Strong sector concentration in Healthcare (3 signals) suggests sector-specific rotation. 5 signals showing insider selling warrant caution.

Trading tips for this strategy:

• Entry timing: Consider entering on next-day weakness or at previous day's close level
• Position sizing: Start small (1-2% of portfolio per signal)
• Stop loss: Below today's low (tight stops for mean reversion)
• Take profit: 3-5% bounce target, or previous day's high
• Time stop: Exit if no bounce in 1-3 days

Risk warning: Mean reversion can fail in strong downtrends - check broader market context

Sharing Call-to-Action

📈 Enjoying the updates? Liking, sharing, or subscribing helps bring this analysis to a wider audience.

Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.

This is not financial advice. Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/